Criteria Fulfill
Item
patients must:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Portopulmonary hypertension Severe | Standard of Care Catheterization of right heart | Treprostinil Planned
Item
1. confirmed severe poph documented on standard of care right-heart catheterization (rhc) with a plan to initiate treprostinil therapy, as recommended by the treating physician state within 30 days.
boolean
C1868851 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C2936643 (UMLS CUI [2,1])
C0189896 (UMLS CUI [2,2])
C1145760 (UMLS CUI [3,1])
C1301732 (UMLS CUI [3,2])
Hypertension, Portal
Item
2. have portal hypertension.
boolean
C0020541 (UMLS CUI [1])
Patients Appropriate Orthotopic liver transplant
Item
3. be otherwise suitable candidates for olt.
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0400447 (UMLS CUI [1,3])
Treprostinil Standard of Care Recommended
Item
4. treprostinil therapy must be recommended by the treating physician per standard of care.
boolean
C1145760 (UMLS CUI [1,1])
C2936643 (UMLS CUI [1,2])
C0034866 (UMLS CUI [1,3])
New York Heart Association Classification
Item
5. be nyha class ii, iii, or iv
boolean
C1275491 (UMLS CUI [1])
Pulmonary Capillary Wedge Pressure | Other Coding | Pulmonary arterial hypertension Severe | Pulmonary artery mean pressure Resting | Pulmonary Vascular Resistance Wood units | Catheterization of right heart | Standard of Care Evaluation
Item
6. have pulmonary capillary wedge pressure (pcw) < 18 mmhg and transpulmonary gradient (tpg) ≥ 15 mmhg severe pah is defined as a resting mean pulmonary artery pressure (mpa) > 25 mmhg and pulmonary vascular resistance (pvr) ≥ 3 wood-units by right-heart catheterization (rhc) performed as part of standard of care evaluation within 30 days of enrollment
boolean
C0086879 (UMLS CUI [1])
C3846158 (UMLS CUI [2])
C2973725 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0428645 (UMLS CUI [4,1])
C0035253 (UMLS CUI [4,2])
C0456261 (UMLS CUI [5,1])
C0439525 (UMLS CUI [5,2])
C0189896 (UMLS CUI [6])
C2936643 (UMLS CUI [7,1])
C1261322 (UMLS CUI [7,2])
Criteria Fulfill
Item
patients must not:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Study Subject Participation Status | Indication Investigational Therapy
Item
1. be taking any investigational therapy as part of a clinical trial for any indication within 30 days of enrollment.
boolean
C2348568 (UMLS CUI [1])
C3146298 (UMLS CUI [2,1])
C0949266 (UMLS CUI [2,2])
Vasodilator Agents Pulmonary Hypertension | bosentan | sitaxsentan | ambrisentan | sildenafil | tadalafil | Epoprostenol | beraprost | Iloprost | Treprostinil Inhaled
Item
2. be receiving any vasodilator treatment for pulmonary hypertension (i.e. bosentan, sitaxsentan, ambrisentan, sildenafil, tadalafil, epoprostenol, beraprost, iloprost, inhaled treprostinil) at the time of enrollment.
boolean
C0042402 (UMLS CUI [1,1])
C0020542 (UMLS CUI [1,2])
C0252643 (UMLS CUI [2])
C1704271 (UMLS CUI [3])
C1176329 (UMLS CUI [4])
C0529793 (UMLS CUI [5])
C1176316 (UMLS CUI [6])
C0033567 (UMLS CUI [7])
C0053336 (UMLS CUI [8])
C0079594 (UMLS CUI [9])
C1145760 (UMLS CUI [10,1])
C0001559 (UMLS CUI [10,2])
Kidney Failure Requirement Hemodialysis
Item
3. exhibit renal failure requiring hemodialysis.
boolean
C0035078 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0019004 (UMLS CUI [1,3])